Genecept™ Assay microsite awarded highest honor in 2013 Interactive Media Awards
CHALFONT, PA – March 18, 2013 – Genomind, a personalized medicine company, was awarded “Best in Class” for their Genecept™ Assay microsite, geneceptassay.com, during the 2013 annual Interactive Media Awards.
The “Best in Class” award is the highest honor awarded in the competition and represents the very best in planning, execution, and overall professionalism. During a comprehensive judging process, sites are reviewed for their design, content, functionality, usability, and browser compatibility. The Genecept Assay microsite won high marks in all categories, including a perfect 100 in functionality.
The Interactive Media Awards are sponsored by the Interactive Media Council, Inc. (IMC), a national nonprofit organization of leading web designers, developers, programmers, advertisers, and other web-related professionals. The annual competition is designed to elevate the standards of excellence in web design, and honor and promote those companies utilizing today’s technology to most effectively share their story.
“Genomind is proud to receive this recognition, but especially pleased to know we have a strong tool to clearly communicate our mission, products, and positive influence to clinicians and patients,” said Scott Storrer, CEO. “The more clinicians know about the Genecept Assay, the more they will use it to help patients suffering from psychiatric disorders receive more effective treatment strategies”.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind